S&P 500 Healthcare Sector SEC Filings — June 10, 2026

10-06-2026

Chewy reported Q1 FY2026 net sales of $3.36B, up 7.7% YoY, with net income of $94.8M ($0.23 diluted EPS) compared to $62.4M ($0.15 diluted EPS) in the prior year. Gross margin improved 50 bps to 30.1%, and Adjusted EBITDA rose 31.4% to $253.1M. However, cash and cash equivalents declined sharply from $860.1M to $485.2M, driven by $200M in share repurchases and $174.8M in cash paid for an acquisition, while inventories increased 16.5% to $1.01B.

• · Share-based compensation expense was $66.9M in Q1 FY2026, down from $74.5M in Q1 FY2025.
• · Net cash provided by operating activities was $108.5M, up from $86.4M in the prior year.
• · Capital expenditures remained flat at $37.7M.
• · Total assets decreased slightly from $3.37B to $3.30B, while total liabilities increased from $2.87B to $2.88B.
• · The company acquired a business for $174.8M in cash during the quarter.
• · Weighted-average diluted shares outstanding decreased from 425.3M to 419.1M due to share repurchases.
• · Trade accounts payable increased to $1.31B from $1.22B, indicating potential supplier financing.

10-06-2026

Brandywine Financial Group's 13F-HR filing for the quarter ended December 31, 2025, reports total holdings valued at $46,061,694 across 45 positions. Major holdings include Procter & Gamble ($6.2M), Novo Nordisk ADR ($5.6M), Fiserv ($5.0M), and Philip Morris International ($4.9M), indicating a concentration in consumer staples and healthcare. The filing shows a significant investment in cryptocurrency-related ETFs, with $10,001,920 in Bitwise XRP ETF and $1,222,024 in the REX-Osprey XRP ETF, while no prior-period comparison is available to assess performance.

• · The portfolio holds 45 positions with total market value of $46,061,694 as of December 31, 2025.
• · The largest single holding is the Bitwise XRP ETF at $10,001,920 (487,423 shares), representing approximately 21.7% of the portfolio.
• · Combined cryptocurrency-related ETF positions (Bitwise XRP ETF + REX-Osprey XRP ETF) total $11,224,344, or about 24.4% of the portfolio, indicating a significant speculative component.
• · Consumer staples companies (Procter & Gamble, Philip Morris, General Mills, Clorox, Kimberly-Clark, Altria) collectively account for over $15.5 million, or roughly 33.6% of the portfolio.
• · The portfolio has notable exposure to energy and materials: Sprott Lithium Miners ETF ($2.69M), Petrobras ($2.74M), Duke Energy ($2.15M), Sunoco ($39K), MPLX ($53K), GE Vernova ($29K), and ProShares Crude Oil ETF ($5K).
• · Healthcare positions include Novo Nordisk ADR ($5.6M), Pfizer ($12K), Hinge Health ($5K), and Oscar Health ($38K).
• · Relatively small positions include Viatris ($971, 78 shares), WSFS Financial ($1,160, 21 shares), Wabtec ($1,494, 7 shares), and GE HealthCare ($4,839, 59 shares), suggesting either legacy holdings or minor tactical trades.
• · No options, convertible bonds, or put/call positions were reported; all entries are common stocks or ETFs.
• · The filing does not provide a comparison to the prior quarter, so quarter-over-quarter changes in holdings are not available.

10-06-2026

Elevance Health reaffirmed its full-year 2026 guidance, expecting at least $19.85 per diluted share in reported shareholders' earnings, including approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the company maintains its outlook for adjusted shareholders' earnings of at least $26.75 per diluted share, and reaffirmed the full-year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. No period-over-period comparisons or new financial results were provided in this filing.

10-06-2026

Corebridge Financial, Inc. (CRBG) provided an update on its merger with Equitable Holdings, Inc., announcing progress on leadership appointments and integration planning, with the transaction expected to close by end of 2026. The combined entity will create a full-scale retirement platform with $90+ billion in assets moving to AllianceBernstein, making it a $1 trillion platform, and is expected to be accretive day one with double-digit accretion by 2029. However, the company faces near-term headwinds from market volatility and lower alternative investment returns, with VII expected to be roughly consistent with Q1 2025 levels and full-year returns in the 1-2% range, below long-term expectations.

• · Leadership first three layers announced; wave two communications expected in coming weeks.
• · Proxy and regulatory filings completed domestically and internationally; FINRA process in flight.
• · Expense synergy pacing: 30% by end of year 1, 75% by end of year 2, remainder shortly after.
• · Revenue synergies include cross-selling Corebridge's fixed annuities and IUL through Equitable's wealth management channel and Equitable's VUL through Corebridge distribution.
• · Nippon Life will own over 15% of the new Equitable, with potential to partner on spread products for Japan.
• · Corebridge's 2025 origination of $55B was split equally among internal capabilities, BlackRock, and Blackstone.
• · Near-term headwinds include market volatility, geopolitical uncertainty, and disruptions in software and private credit.
• · Q2 2026 alternative returns expected lower than Q1 2026; VII expected roughly consistent with Q1 2026.
• · Full-year VII expected in 1-2% range, below long-term expectations.

10-06-2026

News Corp filed an 8-K on June 10, 2026, disclosing its stock repurchase program authorization of up to $1 billion in aggregate of Class A and Class B common stock. The company provided daily transaction disclosures to the Australian Securities Exchange as required, with copies attached as exhibits. The filing includes forward-looking statements regarding the intent to repurchase shares from time to time.

• · The repurchase program covers both Class A common stock (NWSA) and Class B common stock (NWS).
• · Disclosures to the ASX are made on a daily basis for any transactions under the program.
• · The company also discloses repurchase information in its quarterly and annual reports.

10-06-2026

Bread Financial Holdings, Inc. filed an 8-K on June 10, 2026, containing a press release (Exhibit 99.1) with a performance update for the period ended May 31, 2026. The filing is a Regulation FD disclosure; the press release was not filed for Section 18 Exchange Act purposes. The actual performance figures are not included in this 8-K text, only the notice of the press release.

• · Filing type is 8-K under items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• · The performance update press release is attached as Exhibit 99.1 but its content is not included in this filing text.
• · The press release is furnished, not filed, for purposes of Section 18 liability.
• · Company headquarters located at 3095 Loyalty Circle, Columbus, Ohio 43219.

10-06-2026

Anixa Biosciences Inc. reported total assets of $14,865 (USD) as of April 30, 2026, down from $16,080 as of October 31, 2025 (-7.6%). Cash and cash equivalents increased to $1,477 from $1,244 (+18.7%) while short-term investments decreased to $12,209 from $13,930 (-12.4%). For the three months ended April 30, 2026, total operating expenses were $2,647 vs $3,003 in the comparable 2025 quarter (a 11.9% decrease) and net loss improved to $(2,536) from $(2,813) (a 9.8% improvement); however, six-month results show total operating expenses of $5,363 in 2026 vs $6,389 in 2025 (a 16.1% decrease) and net loss of $(5,121) vs $(6,026) (a 15.0% improvement), indicating reduced spending and smaller losses but continued negative earnings and an accumulated deficit of $(256,758).

• · Revenue: $- for all reported periods (no revenue recognized).
• · Accumulated deficit increased to $(256,758) as of April 30, 2026 from $(251,677) as of October 31, 2025 (a $5,081 increase in deficit over six months, consistent with six-month net loss).
• · Net cash used in operating activities for the six months ended April 30, 2026 was $(4,351) compared with $(4,407) for the six months ended April 30, 2025 (slight improvement).
• · Proceeds from maturities of short-term investments were $26,292 for the six months ended April 30, 2026 while disbursements to acquire short-term investments were $(24,642), producing net investing inflow of $1,650.
• · Net cash provided by financing activities was $2,934 for the six months ended April 30, 2026 vs $1 for the six months ended April 30, 2025, driven primarily by at-the-market offering proceeds of $2,870 (net).
• · Non-cash stock-based compensation (R&D + G&A) for the three months ended April 30, 2026 totaled $665 ($286 R&D + $379 G&A) and for the three months ended April 30, 2025 totaled $988 ($417 R&D + $571 G&A).

10-06-2026

IDEAYA Biosciences completed a public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, raising net proceeds of approximately $323.6 million. The offering included full exercise of the underwriters' option for additional shares. The company entered into an underwriting agreement with several underwriters and agreed to a 60-day lock-up period for directors and executive officers.

• · The offering was made under an automatically effective shelf registration statement on Form S-3 (Registration No. 333-295560).
• · The company granted the underwriters a 30-day option to purchase up to 1,666,669 additional shares, which was exercised in full.
• · The lock-up agreement restricts the company and its directors and executive officers from selling or transferring common stock for 60 days after the prospectus date, subject to certain exceptions.
• · The pre-funded warrants are exercisable from issuance until fully exercised, subject to an ownership limitation.

10-06-2026

Virtu Financial, Inc. held its 2026 annual meeting on June 10, 2026, where stockholders elected three Class II directors (Aaron Simons, Joseph J. Grano, Jr., and Joanne M. Minieri) for three-year terms, approved advisory say-on-pay compensation with 98.8% support, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026. All proposals passed with strong shareholder support, though director Joseph J. Grano, Jr. received 16.7 million withheld votes (2.5% of votes cast), and Joanne M. Minieri received 26.3 million withheld votes (3.9% of votes cast), indicating some dissent.

• · Aaron Simons received 671,181,435 For votes and 776,474 Withheld (99.9% approval).
• · Joseph J. Grano, Jr. received 655,260,181 For and 16,697,728 Withheld (97.5% approval).
• · Joanne M. Minieri received 645,673,037 For and 26,284,872 Withheld (96.1% approval).
• · Advisory say-on-pay: 663,861,829 For, 8,042,616 Against, 53,464 Abstain.
• · Ratification of PwC: 679,397,651 For, 659,952 Against, 40,619 Abstain.
• · Broker non-votes were 8,140,313 on all three director and advisory proposals.

10-06-2026

Humacyte, Inc. announced results from its Phase 3 clinical trial (V012) of the acellular tissue engineered vessel (ATEV) in arteriovenous access for female patients with end-stage renal disease requiring hemodialysis. The company also made available an investor presentation for use in investor calls and conferences.

• · The Phase 3 trial (V012) focused on arteriovenous access for female patients with end-stage renal disease requiring hemodialysis.
• · The investor presentation is dated June 2026 and is attached as Exhibit 99.2.

10-06-2026

CoreWeave held its 2026 Annual Meeting on June 8, 2026, with 85.51% of combined voting power represented. Stockholders elected Michael Intrator as a Class I director, ratified Deloitte & Touche as auditor, and approved executive compensation on an advisory basis. The company will hold annual advisory votes on executive compensation going forward.

• · The record date for voting was April 15, 2026.
• · Class A common stockholders had one vote per share; Class B common stockholders had ten votes per share.
• · Proposal 4 (frequency of advisory votes on executive compensation) received 1,149,884,867 votes for 'One Year', 219,374 for 'Two Years', 690,390 for 'Three Years', and 903,910 abstentions.
• · The company will hold an annual nonbinding advisory vote on executive compensation until the next required frequency vote.

10-06-2026

Broadridge Financial Solutions appointed Todd Diganci to its Board of Directors effective August 1, 2026, expanding the board to 10 members, eight of whom are independent. Diganci, former EVP, CFO, and CAO of FINRA, will serve on the Audit Committee. The appointment brings regulatory and financial expertise to support Broadridge's innovation and growth.

• · Broadridge processes over 7 billion communications annually and underpins daily average trading of over $15 trillion in tokenized and traditional securities globally.
• · Broadridge is part of the S&P 500 Index and employs over 15,000 associates in 21 countries.

10-06-2026

Biogen Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, where all ten director nominees were elected, the appointment of PricewaterhouseCoopers LLP as independent auditor for FY2026 was ratified, and the advisory vote on executive compensation was approved. While most directors received strong support (over 120 million votes for several nominees), Eric K. Rowinsky received only 93.6 million votes for (76.8%) with 28.2 million against, indicating notable shareholder dissent. The advisory say-on-pay vote passed with 114.2 million for (93.7% of votes cast), but 7.5 million votes were against.

• · Total outstanding shares eligible to vote not disclosed; broker non-votes were 9,359,127 on all director elections and the say-on-pay proposal.
• · The auditor ratification did not have broker non-votes; total votes cast were 131,266,549.
• · Eric K. Rowinsky received the lowest support among directors with 93,569,685 votes for and 28,216,589 against (23.2% against).
• · Lloyd Minor received the highest support with 121,220,738 votes for (99.5% of votes cast).

10-06-2026

McEwen Inc. held its annual meeting on June 4, 2026, with 57.3% of outstanding shares voted, constituting a quorum. Shareholders elected all 11 director nominees, ratified Ernst & Young as auditor for 2026, and approved the issuance of common stock to Robert R. McEwen. Notably, director John Florek received the highest number of withheld votes (4,316,758), indicating significant shareholder dissent, while all other directors received strong support.

• · Proposal 2 (ratification of EY) passed with 33,905,193 votes for, 129,269 against, and 44,959 abstentions.
• · Proposal 3 (issuance of shares to Robert R. McEwen) was approved by disinterested shareholders with 17,696,367 for, 278,311 against, and 96,004 abstentions.
• · Director John Florek received 22,173,375 votes for and 4,316,758 withheld, the highest withheld count among all nominees.
• · All other directors received over 25 million votes for and fewer than 1.1 million withheld.

10-06-2026

NewCleo Ltd. filed a Form 425 with the SEC on June 10, 2026, regarding its proposed business combination with NewHold Investment Corp III (SPAC). The filing includes an English translation of an excerpt from a presentation by newcleo at a public debate in France. The document contains forward-looking statements and risk factors, and emphasizes that investors should read the upcoming proxy statement/prospectus for important information. No financial figures or quantitative data are provided.

• · The filing is a Form 425 under Rule 425 of the Securities Act and deemed filed under Rule 14a-12 of the Exchange Act.
• · The subject company is NewHold Investment Corp III with Commission File No. 001-42541.
• · The filing includes an English translation of an excerpt from a presentation by newcleo at a public debate in France held on June 10, 2026.
• · The SPAC's final prospectus relating to its initial public offering was dated February 27, 2025.
• · The SPAC's address is 52 Vanderbilt Avenue, Suite 2005, New York, NY 10017.

10-06-2026

On June 5, 2026, an Israeli court approved a debt arrangement for Pacific Oak SOR (BVI) Holdings, Ltd., the indirect wholly owned subsidiary of Pacific Oak Strategic Opportunity REIT, Inc. The arrangement restructures the BVI's Series B and Series D bonds, extending the final maturity to June 30, 2028, and increasing the interest rate from 11.0% to 11.5% after the completion date. While the outstanding principal amounts (NIS 388,237,587 for Series B and NIS 587,063,000 for Series D) are not reduced, the company will receive limited operational funding of up to approximately $2.9 million plus $61,000 per month from the BVI under a second loan, but the BVI faces significant operational restrictions and must maintain a minimum liquidity reserve of $6.0 million.

• · The Debt Arrangement was approved by bondholders before court approval.
• · The BVI's board of directors was reconstituted to include directors supported by bondholders.
• · An administrator was appointed under Israeli insolvency law to decide creditor claims and pursue certain claims on behalf of the BVI, but does not have management authority.
• · The Second Loan does not require the BVI to advance any minimum amount; advances are at the BVI's discretion based on an approved budget and sufficient available funds.
• · The Company and Partnership's sole remedy for BVI breach of the Second Loan is termination; they cannot seek damages.
• · The Company may appoint a director to BVI board meetings subject to bondholder approval.
• · The Company agreed not to initiate insolvency proceedings against the BVI as a condition of the Second Loan.
• · The Second Loan is governed by Israeli law with exclusive jurisdiction in the Tel Aviv–Jaffa District Court.
• · The Company plans to provide an update with related documents on a subsequent Form 8-K upon the Completion Date.

10-06-2026

CID Holdco, Inc. (Dot Ai) announced two non-binding letters of intent: an up to $5.0 million convertible preferred stock investment and the sale of a portion of its operating business for approximately $6.0 million in cash plus assumption of up to $3.0 million in liabilities. The transactions aim to strengthen the balance sheet and support Nasdaq compliance, but there is no assurance they will be completed.

• · The convertible preferred stock investment is to be funded in three tranches.
• · The sale of a portion of the operating business includes designated operating assets used in the Dot Ai business.
• · The buyer would fund a $500,000 secured convertible note as a down payment for exclusivity.
• · The Company retained Cohen & Company Capital Markets as exclusive financial advisor.
• · The Company's common stock trades under DAIC and warrants under DAICW on Nasdaq.
• · The warrants have an exercise price of $287.50 per share after a reverse stock split effective May 29, 2026.

10-06-2026

Medallion Financial Corp. filed an 8-K on June 10, 2026, announcing the preliminary results from its 2026 Annual Meeting of Stockholders via a press release. The filing does not disclose any financial results or performance metrics, only the procedural outcome of the meeting.

• · The press release (Exhibit 99.1) is incorporated by reference but not summarized in the filing.
• · No financial results, revenue, earnings, or operational metrics were disclosed in this 8-K.

10-06-2026

Earth Science Tech, Inc. filed an 8-K on June 10, 2026, disclosing the issuance of a press release announcing its annual shareholder letter for the fiscal year ended March 31, 2026. The filing includes the press release as Exhibit 99.1 and is signed by CEO and Chairman Giorgio R. Saumat. No financial figures or period-over-period comparisons are provided in the filing.

• · The press release was issued on June 10, 2026.
• · The annual shareholder letter covers the fiscal year ended March 31, 2026.
• · The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• · The company's common stock trades on the OTC Bulletin Board under symbol ETST.

10-06-2026

Sprout Social, Inc. announced a transition in the role of Chief Technology Officer. Founder Aaron Rankin, currently a Board member, will reassume the CTO role effective August 3, 2026, replacing Alan Boyce, who resigned after nearly 16 years with the company. The resignation was not due to any disagreement, and Boyce will assist with the transition until the effective date.

• · The transition is effective August 3, 2026.
• · Aaron Rankin will remain a member of the Board of Directors after assuming the CTO role.
• · Alan Boyce's resignation was not the result of any disagreement with the company.
• · A LinkedIn post by Aaron Rankin about the transition is furnished as Exhibit 99.1.

10-06-2026

Pulse Biosciences, Inc. announced on June 10, 2026, that it will deliver an irrevocable election to redeem its outstanding common stock warrants (CUSIP # 74587B143) issued in a July 2024 rights offering. The redemption price is $0.01 per underlying share, and warrants must be exercised for cash by 5:00 p.m. Eastern Time on July 13, 2026, or they will be redeemed at that price. The redemption is triggered because the volume-weighted average price of the company's common stock has equaled or exceeded 200% of the exercise price ($22.00) for 20 consecutive trading days.

• · The warrants were originally issued on July 3, 2024, in connection with the company's rights offering.
• · The redemption election is irrevocable.
• · Outstanding 200% Warrants may be exercised for cash at any time prior to 5:00 p.m., Eastern Time, on July 13, 2026.
• · Any 200% Warrants not exercised by the redemption time will be redeemed for $0.01 per warrant share.
• · The press release is attached as Exhibit 99.1 to the 8-K filing.

10-06-2026

First Real Estate Investment Trust of New Jersey, Inc. (FREIT) filed a definitive proxy statement (DEF 14A) dated June 10, 2026 for its Annual Meeting of Stockholders to be held August 6, 2026. There were 7,482,432 Shares issued and outstanding as of the record date May 29, 2026; stockholders will vote on electing two directors, an advisory vote on executive compensation, and ratification of EisnerAmper LLP as auditors. Insiders (all directors and executive officers as a group) beneficially own 1,568,979 Shares (21% of the class), although certain insiders have pledged 383,388 Shares as collateral, reflecting concentrated insider ownership alongside pledged collateral which can raise governance considerations.

• · Record date for voting: May 29, 2026.
• · Annual Meeting date/time/location: August 6, 2026 at 10 a.m. (EDT) at Holiday Inn Hasbrouck Heights Meadowlands, 283 Route 17 South, Hasbrouck Heights, NJ 07604.
• · Proposals: (1) election of two Directors for three-year terms, (2) advisory vote to approve executive compensation, (3) ratification of EisnerAmper LLP as independent registered public accountants for fiscal year ending October 31, 2026.
• · Insider concentration: 1,568,979 Shares represent 21% of outstanding Shares; this concentration may materially influence votes on the proposals.
• · Pledged insider collateral: an aggregate of 383,388 Shares are pledged by insiders to a banking institution to secure personal indebtedness (disclosed with respect to Mr. Artinian and potentially others).
• · There were 7,482,432 Shares outstanding as of May 29, 2026, which is the base used to compute ownership percentages.

10-06-2026

Citi Trends Inc reported net income of $7.754M for the thirteen weeks ended May 2, 2026, a dramatic increase from $0.871M in the same period last year, driven by a 14.4% YoY rise in net sales to $230.858M. However, selling, general and administrative expenses also rose 6.5% YoY to $79.745M, and inventory increased slightly by 1.5% from the prior quarter-end, indicating persistent cost pressures.

• · No stock repurchases during the quarter vs. $6.315M in repurchases in the prior-year period.
• · Cash provided by operating activities was $20.875M, compared to cash used of $10.969M in the prior-year period.
• · Capital expenditures increased to $5.833M from $2.104M in the prior-year period.
• · Basic earnings per share rose to $0.95 from $0.11; diluted EPS rose to $0.91 from $0.11.
• · Weighted average diluted shares outstanding increased to 8,484,075 from 8,170,456.
• · Store rent expense increased to $17.701M from $16.327M, a YoY increase of 8.4%.

10-06-2026

KeyCorp updated its Medium-Term Note Program on June 10, 2026, authorizing the issuance of Senior Medium-Term Notes (Series U) and Subordinated Medium-Term Notes (Series V) under existing indentures with Deutsche Bank Trust Company Americas. The notes are registered under a Form S-3 registration statement filed on June 5, 2026. No specific issuance amount, pricing, or terms were disclosed in the filing.

• · The Senior Indenture dates back to June 10, 1994, with supplements in 2001, 2013, and 2022.
• · The Subordinated Indenture was supplemented in 2023 (Third Supplemental Indenture).
• · Officers' Certificate and Company Order for both series were executed on June 10, 2026.
• · The filing includes a Distribution Agreement with unnamed agents.

10-06-2026

Kewaunee Scientific Corporation announced via an 8-K filing on June 10, 2026, that it will release its fourth quarter and fiscal year 2026 results on June 23, 2026. The filing includes a press release as Exhibit 99.1 and provides no financial data or performance metrics for the periods.

• · The results release date is June 23, 2026.
• · The filing is an 8-K under Items 8.01 and 9.01, categorized as Other Events.
• · No preliminary financial figures or performance trends were disclosed in this filing.

10-06-2026

CNB Financial Corporation announced a new 2026 Common Share Repurchase Program authorizing up to 500,000 shares or $15,000,000 in aggregate purchase price, effective from June 10, 2026 through June 10, 2027. The program replaces the expiring 2025 plan and allows repurchases via open market or private transactions, subject to market conditions.

• · The program begins on June 10, 2026, the expiration date of the 2025 Common Share Repurchase Program.
• · Repurchases may be conducted through open market purchases, privately negotiated transactions, or other compliant methods.
• · The program may be commenced or suspended without prior notice depending on market conditions and other factors.
• · The repurchase authorization is subject to compliance with any material agreement to which the Company is a party.

10-06-2026

This DEFA14A filing is a follow-up proxy solicitation for the special meeting of the Point Bridge America First ETF (MAGA) scheduled for June 17, 2026. The Board of Trustees recommends voting 'FOR' the proposal. No financial data is included.

• · Special meeting date: June 17, 2026
• · Proxy statement available at vote.proxyonline.com/PBA/docs/specialmeeting2026.pdf
• · Voting methods: touch-tone phone, online, mail

10-06-2026

Solid Biosciences Inc. held its Annual Meeting on June 10, 2026, where shareholders elected three Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan) and ratified the appointment of Ilan Ganot as a Class I director. The meeting also approved a significant increase in authorized common stock from 240,000,000 to 480,000,000 shares and ratified PricewaterhouseCoopers LLP as the independent auditor. All proposals passed with strong shareholder support, though the advisory vote on executive compensation received notable opposition with 6.2 million votes against.

• · The Share Increase Amendment was approved with 85,604,508 votes for, 893,360 against, and 27,502 abstentions.
• · Ratification of PricewaterhouseCoopers LLP as independent auditor passed with 86,420,186 votes for, 70,007 against, and 34,727 abstentions.
• · The advisory vote on executive compensation received 72,596,980 votes for, 6,203,634 against, and 38,755 abstentions, indicating notable dissent.
• · Broker non-votes were 7,685,551 for director elections and the compensation vote, but zero for the auditor ratification and share increase amendment.